Last update 02 May 2024
Hansa Biopharma AB

Hansa Biopharma AB

Public Company|
2007|
Sweden
|
100-250
| STO: HNSA|

Overview

Tags

Neoplasms
Other Diseases
Nervous System Diseases
Enzyme
Antibody drug conjugate (ADC)
Fusion protein

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Enzyme2
Antibody drug conjugate (ADC)1
Fusion protein1

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jun 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
1
Phase 1 Clinical
Approved
1
2
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Imlifidase
( IgG )
Renal transplant rejection
More
Approved
HNSA-5487
-
Phase 1
NiceR
( Enzymes )
Graft Rejection
More
Preclinical
TARG-10
( α10β1 )
Glioblastoma
More
Preclinical
PXL-272092
-
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free